BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis
in chronic liver disease; however, it is invasive, with the potential for serious complications …

Cryoglobulins are present in about a quarter of patients with hepatitis C; in some,
cryoglobulinemia can become symptomatic or even life-threatening. This review …

Background Approximately one-third of all HIV-infected individuals are coinfected with HCV,
many of whom will receive concomitant treatment for both infections. With the advent of …

The development of effective nucleos (t) ide analogs (NAs) against hepatitis B virus (HBV)
has improved the outcome of patients with chronic hepatitis B (CHB). This review updates …

Background & Aims In treatment-naive patients mono-infected with genotype 1 chronic HCV,
treatments with telaprevir/boceprevir (TVR/BOC)-based triple therapy are standard-of-care …

Introduction: Hepatitis C virus is a hepatotropic virus that generally leads to chronic hepatitis
and various harmful sequelae. The lone standard of treatment has been pegylated interferon …

The drug–drug interaction studies for HCV direct-acting antivirals and antiretrovirals are
important in determining the appropriate drug combinations and dosages. The clinical …

Quality indicators are increasingly used as a tool to achieve safe and quality clinical care,
cost‐effective therapy, for professional learning, remuneration, accreditation and financial …

Currently, two direct‐acting antivirals (DAAs) show well‐established efficacy against
hepatitis C virus (HCV), namely, first‐wave protease inhibitors telaprevir and boceprevir …

Background & aim To compare the efficacy of pegylated-interferon (Peg-IFN) α-2a or α-2b
and ribavirin given as dual therapy versus triple therapy (Peg-IFN and ribavirin plus …